<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/78308CAA-8483-45C0-A280-0AB4B6AD9D35"><gtr:id>78308CAA-8483-45C0-A280-0AB4B6AD9D35</gtr:id><gtr:name>Medical Research Council</gtr:name><gtr:address><gtr:line1>Polaris House</gtr:line1><gtr:line2>North Star Avenue</gtr:line2><gtr:postCode>SN2 1FL</gtr:postCode><gtr:region>South West</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/822827CF-1FF0-4180-880C-7099E5E43A73"><gtr:id>822827CF-1FF0-4180-880C-7099E5E43A73</gtr:id><gtr:firstName>Ian</gtr:firstName><gtr:otherNames>George</gtr:otherNames><gtr:surname>Williamson</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_U122785828"><gtr:id>312B4FF0-E29C-4EF0-AEAC-4EFD333D762B</gtr:id><gtr:title>Trial of topical nasal steroids in children with persistent bilateral otitis media with effusion in primary care (GNOME)</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_U122785828</gtr:grantReference><gtr:abstractText>Recurrent middle year infections with fluid collection behind the ear drum is a common condition of childhood and a long term, recurrent illness leading to poor quality of life in the children experiencing the problem and also resulting in substantial costs to the NHS. There is little research on the effective non- invasive treatments for this condition in primary care. This study will evaluate the effectiveness of a nasal steroid for the management of this problem in children seen in primary care. This will be assessed in a randomised controlled trial and the outcomes of interest will be clinical, quality of life, health service and economic outcomes.</gtr:abstractText><gtr:technicalSummary>Otitis Media with Effusion is an almost universal condition of childhood that is often a chronic recurrent illness that results in substantial cost to the NHS with over 200 million pounds per year spent on prescribing and an additional 30 million pounds cost to the NHS for the insertion of grommets (the surgery used to treat the more persistent and/or severe cases). Most children are referred from primary care, but uncertainty on treatments and diagnosis have historically contributed to a broad and at times inequitable gateway to secondary services. Influential publications arising from the Effective Health Care Bulletin that questioned the evidence base for surgery more than 15 years ago led to reduced referrals but more recent findings of TARGET (Trial of Alternative Regimens Glue Ear Treatment) that endorse the benefit of surgery, albeit in selected cases, may lead to increase referral rates, unless more effective management in primary care is achieved. There are, however, no effective existing treatments available in primary care and hence an urgent need to develop this evidence base.||This trial aims to: assess the effectiveness and cost-effectiveness of topical intranasal steroids over 1 year (in total) in a pragmatic clinical trial and build a health economic model of total health care utilization and costs for a cohort of children with this condition if such an intervention were to be applied to them at various stages in the health care system. The study design is a double-blind randomized placebo-controlled trial. The drugs being tested are nasal steroids. The study will recruit children with persistent or recurrent otitis media confirmed as bilateral effusions on tympanometry, between the ages of 3-11years of age from 70 general practices across the country. They will then be followed up at 6-12 months. Outcomes will be assessed using child centred outcomes (e.g. quality of life issues), audiometry and tympanometry and health service resource use which will be used to model the impact of likely changes in referral pattern.||The study has been funded by the NHS R&amp;amp;D Health Technology Assessments Programme and have been developed as a collaboration between the University of Southampton and GPRF.</gtr:technicalSummary><gtr:fund><gtr:end>2008-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2006-04-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>222499</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>82330AE4-B69A-49B1-B3DC-B39248CB3A81</gtr:id><gtr:title>Topical intranasal corticosteroids in 4-11 year old children with persistent bilateral otitis media with effusion in primary care: double blind randomised placebo controlled trial.</gtr:title><gtr:parentPublicationTitle>BMJ (Clinical research ed.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f517b930182ead5a0ec9fba191c93b7"><gtr:id>3f517b930182ead5a0ec9fba191c93b7</gtr:id><gtr:otherNames>Williamson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0959-535X</gtr:issn><gtr:outcomeId>19F300983C3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B3BC4151-616C-4FAF-8C75-68D1DEB4B629</gtr:id><gtr:title>Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.</gtr:title><gtr:parentPublicationTitle>Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/91a7e49f0ec184a6ee8de391cf4a4607"><gtr:id>91a7e49f0ec184a6ee8de391cf4a4607</gtr:id><gtr:otherNames>Dakin H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0962-9343</gtr:issn><gtr:outcomeId>F5FB30CF4D1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C5172E7D-6473-4F6E-82BD-4E2DE57A5334</gtr:id><gtr:title>A double-blind randomised placebo-controlled trial of topical intranasal corticosteroids in 4- to 11-year-old children with persistent bilateral otitis media with effusion in primary care.</gtr:title><gtr:parentPublicationTitle>Health technology assessment (Winchester, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f517b930182ead5a0ec9fba191c93b7"><gtr:id>3f517b930182ead5a0ec9fba191c93b7</gtr:id><gtr:otherNames>Williamson I</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1366-5278</gtr:issn><gtr:outcomeId>4F88A966520</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_U122785828</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>75</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>208C592B-C1B7-4E87-A19A-04E8D9458E50</gtr:id><gtr:percentage>25</gtr:percentage><gtr:text>6.9  Resources and infrastructure (evaluation of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>